{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "SYRE",
  "name": "Spyre Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/SYRE/",
  "json_url": "https://orbyd.app/dossiers/SYRE.json",
  "status": "RECENTLY_EXITED",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) — are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.",
  "invalidation_trigger": "A weekly close below $84 surrenders the post-SPY002-print breakout base and the $85.31 level the June director-fund block cleared at; secondary: SPY003 Part A or SPY072 RA reads out weak/with a class-safety signal, or a superior competing anti-TL1A Phase 3 from Merck tulisokibart or Roche RVT-3101.",
  "catalyst_date": "2026-09-30",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-30",
  "invalidation_fired": true,
  "themes": [
    "precision-biotech-therapeutics",
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Series A Preferred: 346,045 shares outstanding at 2026-06-30, convertible into 13,841,800 common against 88,064,133 common shares outstanding.",
    "A 2026-06-26 sales agreement with TD Securities allows up to $500.0M of at-the-market common stock issuance; nothing was sold under it through 2026-06-30.",
    "SKYLINE Part A readouts are open-label, single-dose, single-arm. The SKYWAY sub-studies are double-blind and placebo-controlled — different evidentiary bars.",
    "Beta 3.03 and short interest at 15.24% of float mean 7-14% single-headline sessions are routine; intraday levels carry little information here.",
    "Officer sales in June-August 2026 ran under Rule 10b5-1 plans, the CFO's adopted 2025-11-10, so their timing carries no read on the September readouts.",
    "Pre-November-2023 price history belongs to predecessor Aeglea BioTherapeutics; long-run charts are not comparable to the current entity."
  ],
  "body_markdown": "## Current Thesis\n\nThe date ambiguity is gone. Third-party trackers had the Q2 report at 2026-08-06 or 2026-08-14; it landed pre-market on 2026-08-04, and it carried the one thing the pipeline had withheld since the 2026-05-05 corporate update. Both remaining 2026 monotherapy readouts — SPY003 (anti-IL-23) SKYLINE Part A induction topline and the SPY072 (anti-TL1A) SKYWAY rheumatoid-arthritis sub-study — moved from \"Q3 2026\" to **September 2026**, on the release and on spyre.com/pipeline. Psoriatic arthritis and axial spondyloarthritis stay in Q4 2026; SKYLINE Part B combination induction data stay in 2027.\n\nThe tape took it. SYRE closed 2026-08-04 at $104.94, up 10.54% ($10.01) after opening $98.27 and trading $97.03–$105.25 — a new 52-week and all-time intraday high, eclipsing the $105.05 printed 2026-07-27. That resolves the three-week coil between $92.37 (2026-07-28 low) and $105.25 upward.\n\nThe narrative leg being bought: a platform that has cleared two of three monotherapy proof-of-concept shots now hands over a dated month for the third, plus its first placebo-controlled efficacy readout, with financing pressure absent. Cameron Turtle attached a timeline to the rheumatology arm for the first time on 2026-08-04 — \"if successful, we look forward to initiating pivotal development of SPY072 next year.\"\n\nOne line of the print deserves care. The headline EPS of −$0.36 against consensus near −$0.73 to −$0.75 was not an operating result. Q2 net loss of $36.2M includes a **$40.0M gain** on the sale of an in-process R&D asset — Immedica's monetization of a priority review voucher tied to the legacy pegzilarginase rights sold in 2023. Strip it and R&D was $65.5M (versus $40.1M in Q2 2025), G&A $16.1M (versus $11.8M), and operating cash use $69.9M.\n\n**Life-cycle: MATURING.** Dating it: the price high is new, the participation behind it is not. The 2026-08-04 breakout traded 831,929 shares against a 20-day average of 1,066,067 — the fourth straight session under 900,000, after 1,513,005 on 2026-07-28 and 1,216,609 on 2026-07-29. Sell-side response to the print was one maintenance note (LifeSci Capital, Buy, $119, 2026-08-04), not a fresh wave; the roster is unchanged at 17 analysts, 16 strong buy and one hold since Wolfe Research moved to Peer Perform on 2026-07-28. The $105.79 average target now sits $0.85 above the closing price. Short interest fell to 12.51M shares at the 2026-07-31 settlement from 13.64M a month earlier. The story is working and well known; the marginal bid is not widening.\n\n## Bull Case\n\n- **Two of three shots cleared, restated without revision on 2026-08-04.** SPY001 Part A (announced 2026-04-13): Robart's Histopathology Index −9.2 (p<0.0001), clinical remission 40%, endoscopic improvement 51%. SPY002 Part A (2026-06-15): RHI −10.7 (p<0.0001), clinical remission 33%, endoscopic improvement 42%. Modified Mayo Score change −3.7 for both.\n- **The Q3 window narrowed to a month.** SPY003 Part A and the SKYWAY RA sub-study both guided to September 2026 on the 2026-08-04 release and the live pipeline page; the company restated it is \"on track for 6 proof-of-concept Phase 2 readouts in 2026.\"\n- **Balance sheet is not the constraint.** $1,145.3M in cash, equivalents and marketable securities at 2026-06-30 ($162.0M cash plus $983.3M marketable securities), including $435.2M net from the April 2026 follow-on. Runway guided into 2H 2029.\n- **Enrollment ran ahead of plan.** All three SKYWAY sub-studies over-enrolled on or ahead of schedule (completion announced 2026-06-03, reiterated 2026-08-04), which is why September is now a month rather than a quarter.\n- **The target itself cleared Phase 3.** Merck's tulisokibart met the primary endpoint of week-12 clinical remission in ATLAS-UC Study 2 on 2026-06-22 — the first anti-TL1A antibody through Phase 3 in ulcerative colitis, on the mechanism SPY002 and SPY072 both use.\n- **A pivotal timeline exists now.** Management's 2026-08-04 statement points to initiating pivotal SPY072 development in 2027 contingent on the RA read, and to combination work outside IBD.\n\n## Bear Case\n\n- **The earnings beat was non-operating.** The $40.0M IPR&D gain carried the −$0.36 print. Operating expense ran $81.6M in the quarter against $51.9M a year earlier, and operating cash use was $69.9M.\n- **Every efficacy number in hand is open-label.** SKYLINE Part A is a single-dose, single-arm monotherapy assessment with no placebo control, per the company's own description. SPY003 in September is the same design. The SKYWAY RA sub-study — double-blind, placebo-controlled, two dose levels, week 12 — is the first placebo-controlled efficacy readout either trial produces, and open-label effect sizes have a long history of compressing against a placebo arm.\n- **Price has caught the consensus.** $104.94 close versus a $105.79 average target across 17 analysts, range $88 to $135. Wolfe's 2026-07-28 downgrade put standalone fair value at $96–$113 against a $165 takeout scenario, so the close sits inside the skeptic's standalone band.\n- **Undrawn issuance capacity is larger than previously visible.** The 2024 $200M sales agreement was terminated 2026-06-26 and replaced the same day with a 2026 sales agreement with TD Securities for up to **$500.0M** of common stock. Nothing was sold under it through 2026-06-30. It remains live at a record price.\n- **Preferred overhang unchanged.** 346,045 Series A shares were outstanding at 2026-06-30, convertible into 13,841,800 common, against 88,064,133 common shares outstanding (78,189,811 at 2025-12-31).\n\n- **Three anti-TL1A antibodies are already in Phase 3** — Merck tulisokibart, Roche/Genentech afimkibart, Sanofi/Teva duvakitug — while Spyre's most advanced asset is in Phase 2 Part B.\n\n## Setup & Price Structure\n\n2026-08-04 close $104.94 (+10.54%), session range $97.03–$105.25, volume 831,929. The prior five sessions: $94.93 (−3.46%, 898,396), $98.33 (−3.12%, 621,726), $101.50 (+3.71%, 851,502), $97.87 (−2.09%, 1,216,609), $99.96 (−0.08%, 1,513,005). Price entered the print at the floor of its range and exited at the ceiling.\n\nThe consolidation that resolved runs 2026-07-20 to 2026-08-04: high $105.25, low $92.37 (2026-07-28 intraday), with a second test at $92.71 on 2026-08-03. That $92 shelf is the structure the breakout is standing on.\n\nTrend backdrop: 50-day average $88.73 and rising, 200-day average $53.17. The 52-week range is $14.51–$105.25, a 545% 52-week change. Float 82.07M of 87.94M shares outstanding, institutional ownership 91.28%, beta 3.03, short interest 12.51M shares or 15.24% of float at the 2026-07-31 settlement with 6.57 days to cover.\n\nCrowding observables, stated without a verdict: coverage is 16 strong buy against one hold; the closing price is within a dollar of the 17-analyst average target; the breakout session traded 78% of the 20-day average volume; short interest has been falling for a month rather than building; an officer 144 was filed the day before the print; and $500M of at-the-market capacity sits registered and undrawn at an all-time high.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-15 (est., no fixed date) — SPY072 SKYWAY rheumatoid-arthritis sub-study topline.** Guided to September 2026. Double-blind, placebo-controlled, two dose levels at week 12 with open-label follow-up through week 36.\n- **~2026-09-15 (est., no fixed date) — SPY003 SKYLINE Part A induction topline.** Guided to September 2026. Open-label, single dose level.\n- **~2026-08-25 (est.) — short interest settlement data for the 2026-08-14 settlement date publishes**, the first positioning read that spans the print.\n\nNothing on this list is a confirmed calendar date inside the next 30 days. The company has fixed a month, not a day, for both September readouts, and has issued no scheduling release for either.\n\n## Elapsed catalysts\n\n- **2026-08-04 — ELAPSED.** Q2 2026 results and corporate update (8-K Item 2.02, Exhibit 99.1). Delivered the September guidance narrowing, the $1,145.3M cash figure, and confirmation of no Q2 ATM draw. The release carried no conference-call detail. *(passed 5d ago)*\n\n## What Would Change Our Mind\n\nSeptember is now the whole argument. If the month closes with either SPY003 Part A or the SKYWAY RA sub-study still undelivered — or with the pipeline page carrying Q4 2026 where it now says September — the guidance narrowing that produced the 2026-08-04 breakout has been withdrawn, and the reason price sits at the $105.79 consensus goes with it.\n\nThe second break is scientific rather than procedural: the RA sub-study is placebo-controlled, and a placebo-adjusted result materially thinner than the open-label Part A effect sizes would say the monotherapy numbers do not survive a control arm. That reads directly across to SPY002 and to the 2027 combination data the $115–$135 targets are built on.\n\nOn the tape, a weekly close below $92 surrenders the 2026-07-20 to 2026-08-04 consolidation floor that the print broke out of ($92.37 intraday 2026-07-28, $92.71 on 2026-08-03), which would place the breakout inside the range that preceded it. Confirming evidence for the crowding read would be shares appearing under the 2026 sales agreement in the Q3 10-Q, a second and third firm joining Wolfe at hold, or the average target drifting toward the $96–$113 standalone band rather than upward after the September prints.\n\n## Correlation Notes\n\n- **Anti-TL1A class beta.** SYRE moves on other companies' data. Merck (tulisokibart), Roche/Genentech (afimkibart) and Sanofi/Teva (duvakitug) all read across; the 2026-06-22 ATLAS-UC Study 2 win was a Merck release that revalidated a Spyre mechanism. Full placebo-adjusted ATLAS-UC numbers at a scientific congress become the benchmark against which SPY002's open-label 33% remission is judged.\n- **Rate and risk-appetite beta.** At 3.03 beta with no revenue and no approved product, valuation is a duration asset. Broad biotech drawdowns move this name more than the mechanism news does on quiet weeks.\n- **Related-party complex.** All four antibodies are licensed from Paragon Therapeutics, and Fairmount Funds sits behind both the Paragon relationship and the Series A Preferred position. Paragon milestone economics and Fairmount's disclosed holdings are the same set of filings a reader should watch.\n- **Chart discontinuity.** Price history before the November 2023 name change belongs to Aeglea BioTherapeutics. Long-run charts and pre-2024 highs describe a different company.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-05T05:43:23+00:00",
  "last_synthesized": "2026-08-05",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}